SCHEMBL2443584

SCHEMBL2443584

O=C(O)CCCBr.c1ccc(P(c2ccccc2)c2ccccc2)cc1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HDAC3 O15379 2/20 0.47
HDAC4 P56524 2/20 0.47
HDAC1 Q13547 2/20 0.47
HDAC7 Q8WUI4 2/20 0.47
HDAC2 Q92769 2/20 0.47
HDAC10 Q969S8 2/20 0.47
HDAC11 Q96DB2 2/20 0.47
HDAC8 Q9BY41 2/20 0.47
HDAC6 Q9UBN7 2/20 0.47
HDAC9 Q9UKV0 2/20 0.47
HDAC5 Q9UQL6 2/20 0.47
MAPK1 P28482 1/20 0.47
ADRA1A P35348 1/20 0.47
SLC6A3 Q01959 1/20 0.47
SMN1; SMN2 Q16637 1/20 0.47
CYP3A4 P08684 1/20 0.46
TDP1 Q9NUW8 1/20 0.46
MAPT P10636 1/20 0.44
RXFP1 Q9HBX9 1/20 0.44
FABP4 P15090 2/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL434414 0.94 HDAC3 (0.52) HDAC3HDAC4HDAC1HDAC7HDAC2
SCHEMBL10472224 0.93 HDAC3 (0.55) HDAC3HDAC4HDAC1HDAC7HDAC2
SCHEMBL11794783 0.93 HDAC3 (0.55) HDAC3HDAC4HDAC1HDAC7HDAC2
SCHEMBL7619905 0.93 HDAC3 (0.55) HDAC3HDAC4HDAC1HDAC7HDAC2
SCHEMBL9665256 0.93 HDAC3 (0.55) HDAC3HDAC4HDAC1HDAC7HDAC2
SCHEMBL9578909 0.93 HDAC3 (0.55) HDAC3HDAC4HDAC1HDAC7HDAC2
SCHEMBL435538 0.88 CYP3A4 (0.50) HDAC3HDAC4HDAC1HDAC7HDAC2
Succinic Acid SCHEMBL7629002 0.83 CYP3A4 (0.60) HDAC3HDAC4HDAC1HDAC7HDAC2
SCHEMBL25222408 0.82 HDAC3 (0.47) HDAC3HDAC4HDAC1HDAC7HDAC2
SCHEMBL9280755 0.82 LMNA (0.47) SMN1; SMN2CYP3A4TDP1MAPTALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 74 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-119978777-A Modified 6-chloro-1H-pyrazolo [4,3-C ] pyridine-alcohol-containing material and preparation method thereof 苏州求索生物科技有限公司 2025-05-13 CN claimed
CN-119709179-A Preparation method of mitochondrion targeting fluorescent probe and application of mitochondrion targeting fluorescent probe in biological imaging 浙江省中医药研究院 2025-03-28 CN claimed
CN-119431924-A Polymer antibacterial material and preparation method thereof 昆山复纳材料科技有限公司 2025-02-14 CN claimed
CN-114097785-A Polysaccharide-based photothermal sterilization material and application thereof in seed protection and grain storage 中国科学院化学研究所 2022-03-01 CN claimed
WO-2021018099-A1 H2O2-RESPONSIVE CROSSLINKING NEAR-INFRARED MOLECULAR PROBE FOR TUMOR MICROENVIRONMENT AND USE THEREFOR 苏州大学 2021-02-04 WO claimed
WO-2025200154-A1 TWO-PART EPOXY COMPOSITION COMPRISING THIOL CURATIVE, AND CATALYST 3M INNOVATIVE PROPERTIES COMPANY (US) 2025-10-02 WO disclosed
CN-119978777-A Modified 6-chloro-1H-pyrazolo [4,3-C ] pyridine-alcohol-containing material and preparation method thereof 苏州求索生物科技有限公司 2025-05-13 CN disclosed
CN-119931676-A Carbon-based soil modifier and preparation method thereof 烟台华伊绿能科技有限公司 2025-05-06 CN disclosed
WO-2025077836-A1 IONIZABLE LIPIDS AND LIPID NANOPARTICLES FOR RNA DELIVERY BEIGENE SWITZERLAND GMBH (CH) 2025-04-17 WO disclosed
CN-119823520-A Antibacterial ABS material and preparation method thereof 山东颐工材料科技股份有限公司 2025-04-15 CN disclosed
CN-119709179-A Preparation method of mitochondrion targeting fluorescent probe and application of mitochondrion targeting fluorescent probe in biological imaging 浙江省中医药研究院 2025-03-28 CN disclosed
US-12246068-B2 Enzymatically activatable peptide-redox modulator conjugates and use thereof BRANDEIS UNIVERSITY (US) 2025-03-11 US disclosed
EP-0266980-A2 Pharmaceutical compositions, comprising a 2,4-diphenyl-1,3-dioxane derivative and an inhibitor of thromboxane A2 synthesis IMPERIAL CHEMICAL INDUSTRIES PLC (GB) 1988-05-11 EP disclosed
US-4683330-A ANTICOAGULANTS, ANTIULCER AGENTS THE UPJOHN COMPANY (US) 1987-07-28 US disclosed
EP-0160495-A2 Cyclopentyl ethers and their preparation and pharmaceutical formulation GLAXO GROUP LIMITED (GB) 1985-11-06 EP disclosed
EP-0159784-A1 Carbacyclin analogues THE UPJOHN COMPANY (US) 1985-10-30 EP disclosed
US-4327092-A USEFUL AS ANTICOAGULANTS AND ANTI-HISTAMINES GLAXO GROUP LIMITED (GB) 1982-04-27 US disclosed
US-4228180-A 7-Oxabicycloheptane and 7-oxabicycloheptene prostaglandin analogs E. R. SQUIBB & SONS, INC. (US) 1980-10-14 US disclosed
US-4130721-A 11-Deoxy PGE2 compounds THE UPJOHN COMPANY (US) 1978-12-19 US disclosed
US-3987072-A CIS-4,5-Didehydro-15- or 16-alkylated 11-deoxy-PGE1 analogs THE UPJOHN COMPANY (US) 1976-10-19 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12246068-B2 Enzymatically activatable peptide-redox modulator conjugates and use thereof GPX1, GPX4, ENPEP HDAC3 3402/4885HDAC4 2298/4885HDAC1 2021/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.